Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Sasanlimab in Advanced ccRCC or pRCC
NCT05665361Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, sasanlimab in clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (PRCC), sponsored by National Cancer Institute. Started Apr 2024; status: recruiting.
02
Drugs
palbociclibsasanlimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT05665361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665361.